Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.
GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to ...
The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen ...
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up ...
When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...
A novel treatment for amyotrophic lateral sclerosis (ALS) caused by mutations in a specific gene called CHCHD10 showed ...
Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, ...
Hosted on MSN
Antisense oligonucleotide strategy reverses HNRNPH2-related neurodevelopmental disorder
Scientists at St. Jude Children's Research Hospital have found that they can reverse the effects of HNRNPH2-related neurodevelopmental disorder using antisense oligonucleotides (ASOs) in preclinical ...
Ludwig-Maximilians-Universität München-led researchers have induced a greater than 60% reduction in seizure frequency in a preterm infant with early-onset SCN2A developmental and epileptic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results